Invex Therapeutics Ltd
Research Invex Therapeutics Ltd (IXC.AX) on Bullrun: market cap AUD 7.78M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIXC.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 7.78M
- Financial periodFY2025
- Net income-AUD 476.87K
- Free cash flow-AUD 652.57K
Valuation Snapshot
latest market cap is AUD 7.78M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | -AUD 476.87K | -AUD 652.57K | n/a | -0.01 | AUD 5.38M | n/a | AUD 5.25M |
| FY2024 | n/a | -AUD 1.64M | -AUD 2.44M | n/a | -0.02 | AUD 6.03M | n/a | AUD 5.69M |
| FY2023 | n/a | -AUD 7.75M | -AUD 6.87M | n/a | -0.1 | AUD 22.47M | n/a | AUD 21.23M |
| FY2022 | n/a | -AUD 3.95M | -AUD 3.38M | n/a | -0.05 | AUD 29.34M | n/a | AUD 28.48M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-10 | AUD 7.78M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Invex Therapeutics Ltd
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of efficacious treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company has a collaboration with Tessara Therapeutics.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Invex Therapeutics Ltd's market cap?
Invex Therapeutics Ltd's market capitalization is AUD 7.78M.
What does Invex Therapeutics Ltd do?
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of efficacious treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company has a collaboration with Tessara Therapeutics. Invex Therapeutics Ltd was incorporated in 2019 and is based in Perth, Australia.